Approval of the Audited Financial Statements for the quarter and year ended March 31, 2026 and recommend Final Divided of Rs. 18/- per equity share i.e. 900% of the Face Value of Rs. 2/- ....
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Limited reported strong FY2026 results with consolidated revenue growing 23% YoY to Rs. 279,580.3 million from Rs. 227,079.0 million. Net profit after tax jumped 62% to Rs. 53,554.7 million from Rs. 33,062.6 million, driven by robust pharmaceutical segment performance and favorable forex gains. The Board recommended a dividend of Rs. 18 per share (900% of face value Rs. 2), aggregating Rs. 8,229.2 million, subject to shareholder approval. Exceptional items included antitrust litigation provisions of Rs. 5,816.9 million, an Astellas settlement of Rs. 8,475.5 million, and a gain of Rs. 6,626.8 million from business divestments. The company also completed acquisitions of VISUfarma B.V. (Rs. 20,902.7 million) and Renascience Pharma Limited during the year.
Strong earnings growth with PAT up 62% indicates operational efficiency improvement. The clean audit opinion with unmodified reports and EBITDA margin expansion are positive signals for shareholders. However, ongoing litigation provisions and settlement costs remain key monitoring items.